Add BrightSurf on Google Email

Search results for “Survival”

1,000+ results for "Survival"

Delays in surgery for advanced esophageal cancer result in significantly worse survival than early surgery

Patients with stage II/III esophageal cancer who received delayed surgery had a relative survival rate that was almost half that of patients who underwent early surgery. Early-stage cancer patients did not experience significant differences in survival rates between those who received immediate versus delayed surgery.

SourceAmerican College of Surgeons·JournalJournal of the American College of Surgeons·DateMay 12, 2022

ARS-developed Varroa-resistant honey bees better winter survivors

A study published in Scientific Reports found that ARS-developed Pol-line honey bees have a significantly higher winter survival rate than standard honey bees, with rates of 62.5% and 3%, respectively. Additionally, Pol-line colonies showed lower levels of three major viruses commonly transmitted by Varroa mites.

SourceUS Department of Agriculture - Agricultural Research Service·JournalScientific Reports·TypeObservational study·DateApr 7, 2022

How does perennial grassland cover affect duck nest survival?

A new study published in The Journal of Wildlife Management found that perennial grassland cover affects duck nest survival differently depending on its dominance as a landcover type. In the Prairie Pothole Region, intermediate levels of perennial cover (30–60%) showed no additional benefits for nest survival.

SourceWiley·JournalJournal of Wildlife Management·DateApr 6, 2022

Critical and underutilized: Fire and police responders associated with higher cardiac arrest survival rates

A new study found that non-medical first responders, such as police and fire departments, are associated with higher cardiac arrest survival rates. They initiated CPR in 31.8% of incidents and AED use in 6.1% of cases, leading to significantly improved chances of survival and hospital discharge.

SourceMichigan Medicine - University of Michigan·JournalResuscitation·TypeData/statistical analysis·DateMar 29, 2022

Wildlife survival after rehabilitation depends on many factors, study finds

A comprehensive study analyzing international literature on wildlife rehabilitation found that human activity is a significant factor influencing outcomes. The study identified five key categories of factors impacting survival outcomes for rescued wildlife, highlighting the need for rehabilitators to mitigate threats and address these ...

SourceMorris Animal Foundation·JournalPLOS ONE·TypeSystematic review·DateMar 23, 2022

Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

A randomized Phase III trial showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with HR+ and HER2- metastatic breast cancer. The median survival was 63.9 months, and the six-year survival rate was 44.2%, compared to 51.4 months and 32% for placebo.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNew England Journal of Medicine·DateMar 9, 2022

Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients

A phase II clinical trial at St. Jude Children's Research Hospital found significantly higher survival rates for children with high-risk neuroblastoma treated with chemoimmunotherapy and the humanized monoclonal antibody hu14.18K322A, resulting in a three-year disease-free survival rate of 73.7% and an overall survival rate of 86%.

SourceSt. Jude Children's Research Hospital·JournalJournal of Clinical Oncology·DateDec 6, 2021

Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases

A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateNov 10, 2021

Novartis unveils new data at ESMO 2021, including compelling longest ever reported median overall survival data in advanced breast cancer, as it continues to push the boundaries of innovation

Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.

Phase III POSEIDON trial shows positive results for patients taking chemotherapy plus durvalumab and tremelimumab

The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...

Black, Hispanic, impoverished people have worse survival rates among teens, adults under 40 with cancer, UTSW review shows

A UT Southwestern Medical Center review of Texas Cancer Registry data found that Black and Hispanic patients under 40 with cancer have lower survival rates compared to their white counterparts. The study also showed that poverty and lack of insurance coverage exacerbate these disparities.

SourceUT Southwestern Medical Center·JournalJNCI Journal of the National Cancer Institute·DateApr 22, 2021

Chemo for glioblastoma may work better in morning than evening

Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.

SourceWashU Medicine·JournalNeuro-Oncology Advances·DateMar 31, 2021

Combination therapy with radiation shows promise in treating glioblastoma

Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new approach combining an anti-psychotic drug, a statin and radiation to improve overall survival in mice with glioblastoma. The triple combination extended median survival 4-fold compared to radiation alone, providing hope for improved treatment options.

SourceUniversity of California - Los Angeles Health Sciences·JournalJNCI Journal of the National Cancer Institute·DateFeb 9, 2021

Closing the racial disparity gap in survival after in-hospital cardiac arrest

A new study from the University of Pennsylvania School of Nursing found that better medical-surgical nurse staffing has a greater effect on black patients than white patients, and differences in survival to discharge after an IHCA are more pronounced in poorly staffed hospitals. The study included over 14,000 patients in 75 US hospitals.

Breast cancer medication risk

A new study published in Frontiers In Oncology found a negative association between beta-blocker use and survival outcomes in patients with HER2 positive advanced breast cancer. The research highlights a subgroup of patients whose survival outcomes are poorer and calls for further investigation to improve treatment outcomes.

SourceFlinders University·JournalFrontiers in Oncology·DateSep 29, 2020

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial

A clinical trial found that patients with IDH-mutant high-risk LGG, regardless of codeletion status, receive a survival benefit from adding postradiation chemotherapy. The study supports the use of WHO-defined molecular subgroups in predicting response to treatment.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateAug 31, 2020

Study shows long-term survival benefit for certain patients with advanced lung cancer

Researchers at Yale Cancer Center discovered that a small amount of the PD-L1 biomarker can predict long-term survival benefits from using pembrolizumab in patients with advanced lung cancer. The study found that overall survival was about 99% one year after discontinuing treatment, and ranged from 23% to 35% three years after treatment.

SourceYale University·JournalJournal of Clinical Oncology·DateFeb 20, 2020